---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-032947"
form_type: "8-K"
ticker: "ALDX"
cik: "0001341235"
company_name: "Aldeyra Therapeutics, Inc."
filed_at: "2025-04-17T23:59:59+00:00"
generated_at: "2026-05-23T11:39:59.242160+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Aldeyra Therapeutics appoints Chip Clark to board of directors

## Summary
- William (Chip) Clark elected as Class I director on April 17, 2025; term expires at 2027 annual meeting.
- Board size increased to eight upon Clark's election.
- Clark received option to purchase 76,760 shares at closing price on April 17, 2025, vesting over 3 years.
- Annual director fee of $40,000 plus eligibility for annual option grant worth ~$130,000.
- Clark is co-founder/CEO of Vibrant Biomedicines, former CEO of Genocea Biosciences.

## SEC filing metadata
- accession: 0001213900-25-032947
- form_type: 8-K
- ticker: ALDX
- cik: 0001341235
- company_name: Aldeyra Therapeutics, Inc.
- filed_at: 2025-04-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1341235/000121390025032947/0001213900-25-032947-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1341235/000121390025032947/ea023875601-8k_aldey.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-032947
- JSON: https://secwatch.observer/filing/0001213900-25-032947.json
- Plain text: https://secwatch.observer/filing/0001213900-25-032947.txt

## Key facts
- Executive change
  William (Chip) Clark was elected as Director at Aldeyra Therapeutics, Inc..
  - Action: elected
  - Role: Director
  source text: the Board elected William (Chip) Clark as a Class I director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1341235/000121390025032947/0001213900-25-032947-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.